Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARVAC-CG Phase 1 in Healthy Adults Previously Vaccinated Against COVID-19
NCT05656508Phase 1Completed
- Sponsor
- Laboratorio Pablo Cassará
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of ARVAC-CG in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Laboratorio Pablo Cassará. Primary endpoints: Solicited local and systemic reactions, Unsolicited adverse events and 2 more. Started Apr 2022; status: completed.
02
Drugs
ARVAC-CG
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05656508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05656508.